PMID- 29191358
OWN - NLM
STAT- MEDLINE
DCOM- 20180214
LR  - 20181202
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 105
IP  - 1
DP  - 2018 Jan
TI  - [Stereotactic body radiation therapy for oligometastatic prostate cancer].
PG  - 120-125
LID - S0007-4551(17)30326-0 [pii]
LID - 10.1016/j.bulcan.2017.09.017 [doi]
AB  - INTRODUCTION: The first line treatment of metastatic prostate cancer is medical 
      or surgical androgen-deprivation. This treatment however has significant side 
      effects that can affect the patients' quality of life. For oligometastatic 
      patients, a new therapeutic approach, focusing on local treatment of metastases, 
      is emerging. METHODS: A systematic review of studies published on Stereotactic 
      Body Radiation Therapy (SBRT) for oligometastatic prostate cancer was performed 
      using results from search request on MEDLINE. RESULTS: Treatment regimens vary 
      from a single fraction of 20Gy (bone lesions) to ten fractions for a total dose 
      of 64Gy (visceral metastases). Local control is 95.5 to 100% at 2 years with 
      grade 1 and 2 toxicities around 10%, without any grade 3 side effects. These 
      retrospective studies show the feasibility and very low toxicity of SBRT for this 
      population of patients. The effect of SBRT on disease-free or global survival and 
      quality of life has not been assessed. Several prospective trials (STOMP & 
      ORIOLE) are underway. CONCLUSION: Treating patients with up to five prostate 
      cancer metastases is efficient and has a low toxicity. Prospective trials should 
      identify which patients, if any, really benefit from this approach.
CI  - Copyright (c) 2017 Societe Francaise du Cancer. Published by Elsevier Masson SAS. 
      All rights reserved.
FAU - Bibault, Jean-Emmanuel
AU  - Bibault JE
AD  - Universite Paris Descartes, Sorbonne Paris Cite, hopital Europeen Georges 
      Pompidou, service d'oncologie radiotherapie, 20, rue Leblanc, 75015 Paris, 
      France. Electronic address: jean-emmanuel.bibault@aphp.fr.
LA  - fre
PT  - Journal Article
PT  - Review
PT  - Systematic Review
TT  - Role de la radiotherapie en conditions stereotaxiques dans la prise en charge des 
      patients atteints d'un cancer de prostate oligometastatique.
DEP - 20171127
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
SB  - IM
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*pathology/*radiotherapy
MH  - Radiosurgery/*methods
OTO - NOTNLM
OT  - Cancer de prostate
OT  - Oligometastatic
OT  - Oligometastatique
OT  - Prostate cancer
OT  - Radiotherapie en conditions stereotaxiques
OT  - Stereotactic body radiation therapy
EDAT- 2017/12/02 06:00
MHDA- 2018/02/15 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/08/09 00:00 [received]
PHST- 2017/09/05 00:00 [revised]
PHST- 2017/09/07 00:00 [accepted]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2018/02/15 06:00 [medline]
PHST- 2017/12/02 06:00 [entrez]
AID - S0007-4551(17)30326-0 [pii]
AID - 10.1016/j.bulcan.2017.09.017 [doi]
PST - ppublish
SO  - Bull Cancer. 2018 Jan;105(1):120-125. doi: 10.1016/j.bulcan.2017.09.017. Epub 
      2017 Nov 27.